We've Got You
[4] [5] The standard of care remains disease-modifying antirheumatic drugs (DMARDs), including conventional synthetic DMARDs like methotrexate as first-line therapy, with escalation to biological DMARDs or targeted synthetic DMARDs if disease activity remains inadequately controlled, following a treat-to-target approach
Without these, the body can revert to old ways, and pounds can sneak back in
She is currently conducting several interventional clinical trials in adolescents with PCOS with the goal of reversing early cardiometabolic disease
GLP-1 Key Research Facts Full name: Glucagon-Like Peptide-1 incretin hormone of the proglucagon family Primary bioactive form: GLP-1(736)amide 30 amino acids, C-terminally amidated Gene source: Proglucagon gene processed by PCSK1 in intestinal L-cells and brainstem NTS neurons In vivo half-life: Approximately 12 minutes rapidly inactivated by DPP-4 (cleaves His7-Ala8 dipeptide) Primary receptor: GLP-1R (GLP-1 receptor) class B G protein-coupled receptor (GPCR) Signalling: GLP-1R activation cAMP elevation PKA/CREB activation glucose-dependent insulin secretion Additional signalling: PI3K/Akt pathway -cell survival, proliferation, and glucose sensitivity Secretion pattern: Biphasic post-meal release from intestinal L-cells early neural/endocrine peak + late direct nutrient-contact peak Fasting plasma level: ~510 pmol/L
These factors support continued adherence to treatment protocols even when visible progress pauses